drugset
Drugs / DX-104
last change Jul 2026 re-read 9 days ago

DX-104

also known as Group B Meningococcal OMV Vaccine
Developed for
meningococcemia
Investigated by
Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)

Trials 1

today NCT07395739 · Ph 1
2027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07395739 Mar 2026 → May 2027 expected meningococcemia Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2026-02-04 Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) Regulatory Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia delonixbio.com ↗
Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, today announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance from China’s National Medical Products Administration (NMPA).

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DX-104 “Participants in this arm will receive three doses of DX-104 at Months 0, 1, and 6.” NCT07395739 ↗
Known as Group B Meningococcal OMV Vaccine “Group B Meningococcal OMV Vaccine (DX-104)” NCT07395739 ↗